Emerging data suggest Retatru tide , a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , could provide a promising development for body treatment. Initial human trials have demonstrated considerable decreases in visceral fat , potentially exceeding current body composition medications . Nevertheless , more stud